Technology | Cardiac Diagnostics | November 20, 2015

Boston Heart Diagnostics Introduces StatinSmart

Personalized test helps identify likelihood of experiencing painful side effects from statin use

November 20, 2015 — Boston Heart Diagnostics announced the launch of StatinSmart, an at-home saliva laboratory developed test that analyzes the SLCO1B1 (Solute Carrier Organic Anion Transporter 1B1) gene for a variant known to increase an individual's risk for developing statin-induced myopathy. 

StatinSmart helps patients understand how their bodies will process a statin and encourages them to discuss with their healthcare provider the type of statin that is best suited to their genotype. With this information, patients can work with their healthcare provider to personalize a plan to lower cholesterol without unnecessary side effects.

Boston Heart currently offers the SLCO1B1 genotype test through healthcare providers, but this is the first time this laboratory-developed test will be offered directly to individuals online at All orders require physician authorization and include support for individuals to discuss their genotype result with their personal healthcare provider.

SLCO1B1 is one of the genes that instructs the enzymes that process statins in the liver. The SLCO1B1 genotype was identified at the University of Oxford in the United Kingdom. Boston Heart holds the exclusive U.S. license for the SLCO1B1 genotype test. To date, Boston Heart has performed over 250,000 SLCO1B1 genotype tests.

Although statins have been shown to significantly lower heart disease and stroke rates, studies estimate that of the 25-50 percent of patients with cardiovascular disease who stop taking their statin medications as directed, 60 percent cite muscle pain as the primary reason for discontinuation. A variant in the SLCO1B1 gene can cause the statin to not be fully processed, with the excess statin then moving through the blood stream into the muscles and causing pain. About 25 percent of the population has one or both variants, making them up to 4.5 to 17 times more likely to suffer muscle aches and pain.  

In a survey of individuals who have experienced side effects from statins in the past and have stopped taking them, 89 percent would consider taking statins again if they could potentially reduce the side effects. Research shows that patients who received SLCO1B1 genotype-guided therapy were more likely to fill their statin prescription, take the medication as directed, and ultimately lower their LDL cholesterol.

StatinSmart includes an easy-to-use saliva kit and is shipped to the individual for collection, then returned to Boston Heart's CLIA-certified and CAP-accredited laboratory in Framingham, Mass., for analysis. A personalized report and other information needed for individuals to prepare to discuss their result with their healthcare provider are accessible through a secure StatinSmart portal.

For more information:

Related Content

Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing | April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing | April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing | April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing | March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing | January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing | July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
News | Blood Testing | March 22, 2016
March 22, 2016 — Critical Diagnostics announced that it entered into a license agreement for the exclusive worldwide
Overlay Init